Advertisement
Research ArticleOncology Free access | 10.1172/JCI65988
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Zhu, Y. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Li, Y. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Haraguchi, S. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Yu, M. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Ohira, M. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Ozaki, T. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Nakagawa, A. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Ushijima, T. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Isogai, E. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Koseki, H. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Nakamura, Y. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Kong, C. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Mehlen, P. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Arakawa, H. in: JCI | PubMed | Google Scholar
1Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, Chiba, Japan. 2Department of Urology, First Hospital of China Medical University, Shenyang, People’s Republic of China. 3Department of Laboratory Animal, China Medical University, Shenyang, People’s Republic of China. 4Department of Pathology, National Center for Child Health and Development, Tokyo, Japan. 5Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan. 6RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. 7Apoptosis, Cancer and Development Laboratory — Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, Lyon, France. 8Cancer Medicine and Biophysics Division, National Cancer Center Research Institute, Tokyo, Japan.
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Find articles by Nakagawara, A. in: JCI | PubMed | Google Scholar
Published June 17, 2013 - More info
Spontaneous regression of neuroblastoma (NB) resembles the developmentally regulated programmed cell death (PCD) of sympathetic neurons. Regressing tumor cells express high levels of the nerve growth factor (NGF) receptors TRKA and p75NTR and are dependent on NGF for survival; however, the underlying molecular mechanism remains elusive. Here, we show that UNC5D, a dependence receptor that is directly targeted by p53 family members, is highly expressed in favorable NBs. NGF withdrawal strongly upregulated UNC5D, E2F1, and p53 in human primary favorable NBs. The induced UNC5D was cleaved by caspases 2/3, and the released intracellular fragment translocated into the nucleus and interacted with E2F1 to selectively transactivate the proapoptotic target gene. The cleavage of UNC5D and its induction of apoptosis were strongly inhibited by addition of netrin-1. Unc5d–/– mice consistently exhibited a significant increase in dorsal root ganglia neurons and resistance to NGF depletion–induced apoptosis in sympathetic neurons compared with wild-type cells. Our data suggest that UNC5D forms a positive feedback loop with p53 and E2F1 to promote NGF dependence–mediated PCD during NB regression.
Neuroblastoma (NB) is one of the most common solid tumors in children and arises from the sympathoadrenal lineage of the neural crest. The enigma of NB is that many tumors found in infants less than 1 year of age frequently regress spontaneously, even though the tumor metastasizes to the liver, skin, and/or bone marrow, designated as stage 4s (1). Accumulating evidence suggests that both genetic and epigenetic changes may affect the clinical behavior of NBs. However, the molecular and biological bases of NB spontaneous regression and aggressiveness remain elusive.
One of the breakthroughs for understanding how NB regresses was the discovery that both TRKA and p75NTR, high- and low-affinity receptors, respectively, for nerve growth factor (NGF), are expressed at significantly high levels in favorable NBs (2, 3), whereas TRKB and its ligands, brain-derived neurotrophic factor (BDNF) and neurotrophin 4/5 (NT4/5), are highly expressed in aggressive NBs in an autocrine and/or paracrine manner (4). It has been hypothesized that the quantitative relationship between NGF and its receptor complexes within tumor tissue, as well as the acquisition of NGF dependence, may be crucial to inducing NB regression (5).
Recent progress in developmental neurobiology has shown that some important molecules, such as p53 (6), p63 (7), and E2F1 (8, 9), as well as the c-JUN/EGLN3/KIF1Bβ pathway (10–12), are involved in the regulation or induction of NGF depletion–induced programmed cell death (PCD) of sympathetic neurons. Recently, Bredesen and colleagues proposed a new “dependence receptor” concept, which was originally initiated from the idea of the NGF dependence of developing neuronal cells: some receptors display 2 completely opposing actions depending on the availability of their ligands (13). In the presence of their ligands, the receptors transduce a “positive” signal for differentiation, migration, or survival; conversely, those receptors conduct a “negative” signal to trigger apoptosis in the absence of any ligand (13). To date, a growing number of dependence receptors have been identified, including deleted in colorectal cancer (DCC; ref. 14), Ret (15), UNC5 (16, 17), Patched (18), neogenin (19), ALK (20), and integrins such as αvβ3 and α5β1 (21).
To identify the genes that play a key role in both developmentally regulated neuronal PCD and spontaneous regression of NB, we previously generated cDNA libraries from primary NB tissues and identified UNC5D as one of the genes highly expressed in the favorable subset (22). UNC5D is the fourth member of the human dependence receptor UNC5 family (17) and shares the same ligand, netrin-1 (encoded by NTN1), with other UNC5 family members and the tumor suppressor DCC (23). The UNC5 family possesses the intracellular Zo-1–like (ZU5) domain and death domain (DD) as well as putative caspase cleavage sites (13). Previous in vitro and in vivo studies of the UNC5 mouse homologs UNC5A, UNC5B, and UNC5C suggest that they all function as proapoptotic receptors by receiving cleavage of the intracellular region by caspases, which is strongly inhibited by binding of netrin-1 (13, 16). Tanikawa et al. have shown that UNC5B is a direct transcriptional target of the tumor suppressor p53 and mediates p53-induced cell death (24). We also previously found that UNC5D is directly targeted by p53 for its expression (17). In addition, knockout mice of Unc5a, Unc5b, and Unc5c have shown different phenotypes (25–27). However, the functional role of UNC5D remains unclear.
In the present study, we explored the functional role of UNC5D in NGF depletion–induced PCD using primary NB cells as well as Unc5d–/– mouse–derived neuronal cells. Our results showed that NGF depletion–inducible UNC5D formed a positive feedback loop with p53, E2F1, and caspases to accelerate NGF deficiency–mediated cell death.
High-level expression of UNC5D, but not netrin-1, is associated with favorable prognosis of NB. UNC5D was selected from our NB cDNA project as a differentially expressed gene between favorable and unfavorable subsets (Supplemental Figure 1A; supplemental material available online with this article; doi: 10.1172/JCI65988DS1). Quantitative RT-PCR analysis using 108 primary NBs revealed that expression levels of UNC5D mRNA were significantly higher in favorable NBs than unfavorable ones (Figure 1A). Immunohistochemical analysis also showed that, similar to TRKA, UNC5D was positive in tumor cells from favorable NBs with a tendency to regress spontaneously (Figure 1B, Supplemental Figure 2, and Supplemental Table 1). Furthermore, high levels of UNC5D mRNA expression were significantly associated with a favorable outcome (P = 0.003; Figure 1C and Supplemental Table 2). More interestingly, expression levels of UNC5D significantly segregated the patients with NB in advanced stages 3 and 4 into those with good and poor prognosis (P = 0.029; Figure 1C). However, expression of UNC5A as well as UNC5B and UNC5C showed no prognostic significance in primary NBs (Supplemental Figure 1 and Supplemental Table 2). Multivariate analysis indicated that expression of UNC5D was a significant prognostic factor independent of age, stage, and TrkA expression and marginally of DNA ploidy, but not of MYCN amplification (Supplemental Table 3). Notably, expression of NTN1, a ligand of DCC and the UNC5 family, was similar at the mRNA level among all stages of NB (Figure 1A). At protein levels, netrin-1 was barely positive in both favorable and unfavorable NB cells, except in some stromal cells (Figure 1B and Supplemental Figure 2). Thus, netrin-1 appeared to be relatively deficient within the NB tissues, which suggested that the expression pattern of UNC5D/netrin-1 was very similar to that of TRKA/NGF in primary NBs (2). Furthermore, enforced expression of UNC5D led to a decrease in the number of G418-resistant colonies and induced apoptotic cell death in several NB cell lines (Figure 2), which suggests that UNC5D may play a proapoptotic role in NB.
UNC5D is a novel favorable prognostic indicator for NB. (A) Expression of UNC5D and NTN1 mRNA in 108 primary NBs detected by quantitative RT-PCR. Data represent mean ± SD. *P < 0.05; **P < 0.01. (B) Representative images of UNC5D, netrin-1, and TRKA immunohistochemical analysis in favorable (F) and unfavorable (UF) NBs. Original magnification, ×400. (C) Kaplan-Meier survival curves based on higher or lower expression levels of UNC5D mRNA in 108 patients and the unfavorable subset.
UNC5D inhibits cell growth and induces apoptosis in NB cell lines. (A) Colony formation assay for SK-N-BE cells transfected with the indicated plasmids. 48 hours after transfection, cells were transferred to fresh medium containing G418 (400 μg/ml) for 2 weeks. G418-resistant colonies were stained with Giemsa solution and photographed. Data represent mean ± SD of 2 independent experiments. *P < 0.01. (B) Apoptosis was evaluated by TUNEL assay in SH-SY5Y and SK-N-BE cells transfected with the indicated plasmids for 48 hours. Data represent mean ± SD of 3 independent experiments. *P < 0.01. Original magnification, ×100.
UNC5D is induced during NGF withdrawal–triggered apoptosis. We previously hypothesized that, similar to the physiological PCD that occurs in developing sympathetic neurons, the NGF dependence of NB cells could be one of the main causes of NB spontaneous regression (2, 5). We therefore examined the expression of the UNC5 family before and after depletion of NGF in favorable NB cells in primary culture. NGF treatment enhanced cell survival and induced neurite outgrowth in NB cells prepared from 2 tumors with favorable biology (case 1, 9 months old, stage 1, single copy of MYCN, high TRKA expression, and aneuploidy; case 2, 18 months old, stage 3, single copy of MYCN, high TRKA expression, and aneuploidy; Figure 3, B and E). Subsequent withdrawal of NGF triggered apoptotic cell death (Figure 3, A and C), which was significantly inhibited by addition of netrin-1 (Figure 3, D and E). Of interest, only UNC5D among the UNC5 family members was strongly induced — along with p53, E2F1, and BAX, which are already known to be induced in response to NGF depletion (6, 9, 28) in NGF-deprived cells — at both the mRNA and the protein level (Figure 3, B and C), whereas expression of NTN1 was consistently almost undetectable. It was notable that the induced UNC5D protein appeared to be mainly localized in the nuclei of NB cells, as observed using the antibody recognizing the C terminus of the protein (Figure 3C). Another netrin-1 receptor, DCC, was weakly induced in case 1 tumor cells on day 6 after NGF treatment, but was not further induced after NGF deprivation (Figure 3B), which suggests that DCC is more likely to be involved in NGF-induced NB differentiation.
UNC5D is involved in NGF withdrawal–induced apoptosis. (A) Apoptosis assay of primary NB cells from a stage 1 tumor treated with NGF for 4 days, followed by NGF treatment or NGF withdrawal for 2 additional days as indicated. Data represent mean ± SD. (B) Semiquantitative RT-PCR analysis of primary NB cells from case 1 (9 months old, stage 1, single copy of MYCN, high TRKA expression, and aneuploidy) and case 2 (18 months old, stage 3, single copy of MYCN, high TRKA expression, and aneuploidy) treated as in A. (C) Confocal images of UNC5D immunostaining in primary NB cells treated as in A. Nuclei were stained with DAPI. Original magnification, ×200. (D) Apoptosis assay of primary NB cells treated as in A, with or without addition of increasing amounts of netrin-1. Data represent mean ± SD. *P < 0.01. (E) Light microscopic images of primary NB cells in D. Original magnification, ×40. (F) Light microscopic images of primary sympathetic neurons after NGF depletion. Primary sympathetic neurons were isolated from SCG of P0 wild-type and Unc5d–/– mice and cultured for 5 days with NGF-containing medium. Neurons were then treated with or without NGF for an additional 3 days. Scale bars: 100 μm.
To test the in vivo function of UNC5D, we generated mice with knockout of Unc5d, a mouse homolog of human UNC5D (S. Haraguchi and A. Nakagawara, unpublished observations). The primary sympathetic neurons were isolated from superior cervical ganglia (SCG) of P0 Unc5d–/– or wild-type mice. NGF treatment induced neurite outgrowth of primary sympathetic neurons obtained from both wild-type and Unc5d–/– mice to a similar extent. However, after NGF depletion, neuronal death was attenuated in Unc5d–/– versus wild-type sympathetic neurons (Figure 3F). Consistently, the number of neuronal cells isolated from the dorsal root ganglia (DRG) of Unc5d–/– mice was significantly higher than that from wild-type mice (Table 1).
Because most NB-derived cell lines cannot respond to NGF treatment owing to defects in their NGF/TRKA signaling pathway, we used rat PC12 pheochromocytoma cells, a model system commonly used for studying NGF deprivation–mediated neuronal death. Similar to human primary NB cells, induction of UNC5D was also observed in PC12 cells during the early phase of NGF depletion–induced apoptosis (Supplemental Figure 3, A and B). To further elucidate the involvement of UNC5D in NGF withdrawal–triggered apoptosis, we knocked down UNC5D with Accell siRNA in PC12 cells. As a result, UNC5D-knockdown PC12 cells had attenuated cell death in response to NGF deprivation (Supplemental Figure 3F).
Thus, the netrin-1 receptor UNC5D appears to play a critical role in NGF depletion–induced apoptosis, both in human favorable NB cells and in rodent neurons.
UNC5D is cleaved by caspases 2 and 3. Notably, induced UNC5D was detected in the nuclei using the antibody recognizing the C-terminal region of UNC5D (Figure 3C), which indicates that UNC5D may function in the nucleus. Amino acid sequence alignment showed that UNC5D possessed a conserved consensus caspase cleavage sequence, VDVID416, recognized by both caspase 2 and caspase 3/7 (Figure 4A), which suggests that the UNC5D receptor may be cleaved by caspases. We therefore transfected UNC5D into U2OS cells, which underwent apoptotic cell death accompanied by the activation of caspase 3 (Figure 4B). Surprisingly, overexpressed UNC5D protein was detected as several smaller bands besides the full-length one by a specific antibody recognizing the C terminus of UNC5D. Those smaller bands partially disappeared in the presence of a caspase 3/7 inhibitor and completely with the addition of the pan-caspase inhibitor zVAD-fmk (Figure 4C). Furthermore, in vitro caspase cleavage assay revealed that caspases 2 and 3 both cleaved UNC5D at the D416 site, generating a fragment of approximately 60 kDa (Supplemental Figure 4, A and B), which was detectable in UNC5D-expressing cells but not in D416N mutant–expressing cells in response to cisplatin (CDDP; Figure 4D). These data clearly showed that UNC5D was a direct substrate of caspases 2 and 3.
Induced UNC5D is cleaved by caspases, and the released UnICD enters into the nucleus. (A) Schematic of UNC5D protein. TM, transmembrane; iDCC, interaction with DCC. (B) IB analysis of U2OS cells transfected with UNC5D. (C) Overexpressed UNC5D was cleaved by caspases in U2OS cells. UNC5D was probed by a specific antibody recognizing the C terminus. PI, pan-caspase inhibitor; casp3/7 inhi, caspase 3/7 inhibitor. (D) IB analysis of U2OS cells transfected with UNC5D or the D416N mutant in response to CDDP. (E) Immunofluorescent analysis of U2OS cells transfected with the indicated plasmids. Original magnification, ×400. (F) Representative confocal images of UNC5D immunostaining in regressing NB tissue from a stage 1 tumor. Histology of the samples was indicated by H&E staining. Netrin-1 was detected by immunohistochemical staining. Original magnification, ×200; ×400 (insets).
Caspase-released UnICD translocates into the nucleus. To investigate whether UNC5D nuclear staining was due to nuclear translocation of the intracellular fragment of UNC5D (UnICD) released by caspases, we next introduced UnICD into U2OS cells. As expected, expressed UnICD was present predominantly in the nucleus (Figure 4E and Supplemental Figure 4D). Moreover, the nuclear signals were observed in full-length UNC5D–transfected cells, but not in those treated with a pan-caspase inhibitor or transfected with the D416N mutant (Figure 4E). Furthermore, we transfected U2OS cells with the plasmid encoding mouse UNC5D with a FLAG-tag attached to the N terminus of the protein. The amino acid sequence of mouse UNC5D has 96% similarity to the human homolog. Double immunostaining with monoclonal anti-FLAG antibody and polyclonal anti-UNC5D antibody recognizing the C terminus demonstrated that the nuclear signals were detected only by the anti-UNC5D antibody; that is, the C-terminal fragment of UNC5D had entered into the nucleus (Supplemental Figure 4C). Taken together, our results demonstrated that the caspase-released UnICD translocated into the nucleus. Furthermore, nuclear expression of UNC5D was also observed in regressing NB tissue obtained from a patient in stage 1, who had been found by mass screening at the age of 6 months (Figure 4F). However, netrin-1 expression was almost undetectable in the same area.
Previously, we identified that UNC5D is a direct target of p53 (17). In addition to the response to NGF withdrawal, UNC5D was also induced by genotoxic reagents (adriamycin and CDDP) and by TNF-α treatment in p53–wild-type cells (SH-SY5Y and U2OS) and in p53-inactivated HeLa cells (Supplemental Figure 5B), which indicates that UNC5D may be inducible in both a p53-dependent and -independent manner in response to multiple stresses. Indeed, besides p53 (17), p63 and p73 also upregulated UNC5D mRNA (Supplemental Figure 5C), indicating that UNC5D is a common target of the p53 family. Induced UNC5D was cleaved, and then the released UnICD translocated into the nuclei, in U2OS cells as well as the NB cell line SH-SY5Y receiving these cellular stresses (Supplemental Figure 5D). Collectively, these findings suggest that caspase cleavage of UNC5D and subsequent nuclear translocation of UnICD are the common mechanisms that respond to various proapoptotic stimuli.
To further evaluate the functional significance of UNC5D protein cleavage by caspases, we next expressed full-length UNC5D, UnICD, DD, or the D416N mutant in HeLa, U2OS, and HEK293T cells. Introduction of UNC5D, UnICD, and DD into these cells was sufficient to reduce formation of G418-resistant colonies, inhibit anchorage-independent cell growth, and induce apoptosis to similar extents (Figure 5 and Supplemental Figure 4E). However, addition of the pan-caspase inhibitor or expression of the D416N mutant abolished these effects. Thus, the caspase cleavage of UNC5D may be crucial to initiating UNC5D-induced apoptosis, and the C-terminal DD in the released UnICD could be essential to its proapoptotic function.
UnICD with DD has proapoptotic activity. (A) HEK293T cells were transfected with mock, UNC5D, UnICD, DD, and the D416N mutant. Cells transfected with UNC5D were treated with or without a pan-caspase inhibitor. Expressions of these plasmids were detected by IB analysis with the indicated antibodies. (B) Colony formation assay of HeLa cells transfected as in A. (C) Soft agar assay of HeLa cells treated as in A. Original magnification, ×16. (D) TUNEL assay of HEK293T cells treated as in A. Original magnification, ×100. (E) Cell death of HEK293T cells in D was measured by the Trypan blue exclusion assay. Original magnification, ×16. Data in B–E represent mean ± SD (n = 3). *P < 0.01.
Coincident with the above observations in human cells, induction of UNC5D and nuclear translocation of the caspase-released UnICD were detected in wild-type mouse embryonic fibroblasts (MEFs) in response to various apoptotic stimuli (Supplemental Figure 6, A–C). Notably, Unc5d–/– MEFs showed more substantial resistance to CDDP treatment than the wild-type cells (Supplemental Figure 6D), suggestive of an important role of UNC5D in the regulation of stress-induced apoptosis in mice.
Netrin-1 inhibits the proapoptotic activity of UNC5D by preventing its cleavage. Dependence receptors display 2 completely opposing actions depending on the availability of their ligands (13). We next tested the effect of netrin-1 on the proapoptotic function of UNC5D. Addition of netrin-1 prevented the cleavage of UNC5D as well as that of caspase 3 and PARP in a dose-dependent manner (Figure 6A), inhibited nuclear translocation of UnICD (Figure 6B), and, consequently, suppressed cell death in U2OS cells transfected with full-length UNC5D (Figure 6, C and D), whereas it had no effect in UnICD-expressing cells (Figure 6, B–E). Thus, netrin-1 may inhibit the proapoptotic activity of UNC5D by preventing UNC5D cleavage and subsequent nuclear translocation of released UnICD.
Netrin-1 blocks UNC5D cleavage and UNC5D-induced apoptosis. (A) U2OS cells transfected with the indicated plasmids were treated with or without CDDP (40 μM) along with increasing amounts of netrin-1 for 24 hours, followed by IB analysis. (B) U2OS cells transfected with UNC5D or UnICD for 24 hours were treated with or without netrin-1 for an additional 24 hours, followed by immunofluorescent staining. Original magnification, ×400. (C and D) SH-SY5Y cells were transfected with the indicated plasmids and treated with or without a pan-caspase inhibitor or netrin-1. Cell death was evaluated by TUNEL assay (C; original magnification, ×100) and Trypan blue exclusion assay (D). Data represent mean ± SD (n = 3). (E) U2OS cells transfected with UnICD were treated with or without increasing amounts of netrin-1 for 24 hours, followed by IB analysis.
UnICD functions as a transcriptional coactivator. Translocation of UnICD from the cytoplasm into the nucleus implicated the possibility that nuclear UnICD may ultimately promote apoptosis through activation of a set of apoptosis-related genes like NICD and AICD, intracellular fragments derived from Notch 1 (29) and β-APP (30), respectively. Similar to NICD and AICD, UnICD does not contain the DNA-binding domain, which suggests that UnICD is very likely to act as a coactivator of some transcription factors.
To prove this hypothesis, the Gal4 DNA binding domain–fused UnICD (referred to herein as Gal4-UnICD) was transfected into U2OS or HeLa cells together with pGL4.31, which encodes for the luciferase reporter under the control of the Gal4 upstream activation sequence. As a result, Gal4-UnICD significantly enhanced transcription of the reporter gene in both cell lines (Figure 7A), thereby demonstrating that UnICD has transactivation activity independent of p53. Moreover, the transcriptional activity of UnICD relied on the DD in the C terminus (amino acids 859–953; Figure 7C).
UnICD has transactivation activity. (A) Luciferase reporter assay using HeLa and U2OS cells transfected with Gal4-UnICD as indicated. pM-VP16 was used as a positive control. Data represent mean ± SD. (B) UnICD and its deletion mutants. (C) Luciferase reporter assay using HeLa cells transfected with Gal4-UnICD or its deletion mutants as in B. pM-VP16 was used as a positive control. Data represent mean ± SD.
UnICD interacts with E2F1 and selectively transactivates its proapoptotic genes. As reported previously (8, 9) and as shown in Figure 3B, NGF depletion induced expression of E2F1 in neuronal cells, which suggests that nuclear UnICD may function as a coactivator of E2F1. To explore this possibility, we tested the expression patterns of both E2F1 and UnICD. As expected, E2F1 was colocalized in the nucleus with UnICD in cotransfected HeLa cells (Supplemental Figure 7C). Moreover, nuclear colocalization of induced UNC5D and E2F1 was observed in both NGF-depleted primary NB cells (Figure 8A) and CDDP-treated HeLa cells (Supplemental Figure 7D). Because of the limited availability of primary NB cells, we investigated the time course of nuclear accumulation of E2F1 and UnICD in response to CDDP in HeLa cells. E2F1 increased in the nucleus at 6 hours after CDDP treatment, followed by UnICD at 12 hours (Figure 8B). Furthermore, coprecipitation of UnICD with E2F1 protein was found in nuclear extracts prepared from not only UnICD/E2F1-cotransfected HeLa cells (Supplemental Figure 7E), but also CDDP-treated SH-SY5Y cells (Figure 8C), indicative of a physical interaction between the 2 molecules in the nucleus.
Nuclear UnICD promotes apoptosis as a cofactor of E2F1. (A) Immunofluorescent staining of endogenous UNC5D and E2F1 was conducted in primary NB cells treated as in Figure 3A. Original magnification, ×400. (B) Nuclear extracts were prepared from HeLa cells treated with CDDP (20 μM) for the indicated time periods and analyzed by IB. (C) Nuclear extracts were prepared from SH-SY5Y cells treated with CDDP (10 μM, 24 hours) and subjected to IP, followed by IB with the indicated antibodies. (D) Semiquantitative RT-PCR using the cDNAs generated from SH-SY5Y cells transfected with the indicated expression vectors. (E) HeLa cells transfected with siRNAs against E2F1 or a negative control for 24 hours were then transfected with UnICD for an additional 48 hours, followed by semiquantitative RT-PCR. (F) Expression of the E2F1 proapoptotic targets was measured by semiquantitative RT-PCR in wild-type and Unc5d–/– MEFs treated with or without CDDP.
We next used ChIP assay to examine whether the UnICD/E2F1 complex binds to the promoter of the caspase 7 (CASP7) gene, which is a direct target of E2F1 (31). Endogenous UnICD was recruited to the E2F1-binding region in the CASP7 promoter in response to CDDP (Supplemental Figure 7F), which suggests that UnICD may be involved in the function of E2F1 to induce the target genes.
Because E2F1 possesses the dual function of both oncogene and tumor suppressor (32), we next examined target genes of the UnICD/E2F1 transcriptional complex. Enforced expression of UnICD in SH-SY5Y, U2OS, and HeLa cells induced the expression of E2F1 proapoptotic target genes, including CASP3, CASP7, CASP9, BID, and E2F1 itself (ref. 33, Figure 8D, and Supplemental Figure 7G), which were consistently abrogated by 2 kinds of siRNA against E2F1 in UnICD-transfected HeLa cells (Figure 8E and Supplemental Figure 7B). Similarly, induction of these genes was decreased in Unc5d–/– versus wild-type MEFs treated with CDDP (Figure 8F). On the other hand, several growth-promoting target genes of E2F1, including cyclin E, c-Myc, and TK1, were not induced in those UnICD-transfected cells (Supplemental Figure 7H), which suggests that UnICD-mediated apoptosis may be attributed to the selective upregulation of proapoptotic target genes of E2F1. Notably, upregulation of these E2F1 proapoptotic target genes was also observed in NGF-deprived primary NB cells (Supplemental Figure 7I), demonstrating that the UnICD/E2F1 complex plays a pivotal role in NGF depletion–induced apoptosis.
The data presented herein revealed that UNC5D is involved in NGF deficiency–induced PCD in human NB cells with NGF dependence. Among UNC5 family members, only UNC5D was strongly induced in response to NGF depletion. High levels of UNC5D mRNA expression were significantly associated with favorable outcomes in patients with NB, which has the ability to undergo spontaneous regression. We propose a model whereby NGF deficiency triggers induction of UNC5D, E2F1, and p53 in NB cells. Under the relative deficiency of netrin-1, the induced UNC5D is prone to be cleaved by activated caspases, and the released UnICD translocates into the nucleus and forms a complex with E2F1, which in turn selectively induces E2F1 proapoptotic target genes to enhance cell death (Figure 9). UNC5D is a direct target of p53 (17); thus, in cooperation with E2F1 and p53, UNC5D may contribute to PCD by intensifying cell death signaling in regressing NBs.
Induction of cell death by each UNC5 family member appears to occur by different mechanisms. UNC5A mediates apoptotic cell death by interacting with NRAGE via its ZU5 domain (34), while UNC5B requires its DD to recruit death-associated protein kinase (DAPK) in the induction of apoptosis (35). Intriguingly, only UNC5D among the UNC5 family members was inducible in response to NGF depletion (Figure 3B). In support of this, expression levels of UNC5D mRNA were significantly higher in favorable NBs (Figure 1A). High levels of UNC5D mRNA expression were significantly associated with favorable outcome in NBs (Figure 1C). In our study, we did not detect a significant increase in the expression levels of UNC5D mRNA in stage 4s tumors. One of the reasons may be the small sample number; only 6 of 108 primary NB cases tested in our analysis were stage 4s. In addition, we found that UNC5D was induced only in NGF-deprived NB cells, not in NGF-differentiated ones (Figure 3B). Furthermore, many or most of the NB cells with induced expression of UNC5D mRNA might already have died of NGF deficiency in stage 4s tumors. Therefore, it seems that increased expression of UNC5D mRNA may not be observed in spontaneously regressing stage 4s tumors in which extensive tumor cell death and differentiation have occurred. To clarify this, a large sample size will need to be investigated. On the other hand, several population-based screening studies suggest that spontaneous regression also predominantly occurs in stage 1 and 2 patients who have localized tumors (36–38). It should be noted that induction and nuclear localization of UNC5D were observed in regressing NB tissue obtained from a patient in stage 1, who had been found by mass screening at the age of 6 months (Figure 4F), which suggests that UNC5D is involved in NB regression. Moreover, the number of neuronal cells isolated from the DRG of Unc5d–/– mice was significantly higher than that from wild-type mice (Table 1), and Unc5d–/– sympathetic neurons showed the attenuated response to NGF removal (Figure 3F). These findings suggest that UNC5D may have a crucial function in the NGF depletion–triggered PCD process occurring in both developing peripheral neurons and sympathoadrenal lineage-derived NBs dependent on NGF for survival. Because our studies have been mainly conducted using in vitro cell systems, our findings give suggestive clues for developmentally regulated PCD in developing sympathetic neurons with NGF dependence. Further approaches using sympathetic neural progenitor cells should facilitate a better understanding of the molecular mechanism of NGF deficiency–induced neuronal PCD.
Here, we found that netrin-1 protein was positive only in some stromal cells following immunohistochemistry (Figure 1B). In regressing NBs, netrin-1 was almost negative (Figure 4F). Therefore, similar to NGF, the amount of netrin-1 in NB tissues appears to be relatively deficient, which supports the role of UNC5D and its proapoptotic function in spontaneously regressing NBs. Recently, it has been reported that netrin-1 may act as a survival factor for enhancing cell growth and invasion in an autocrine manner in metastatic stage 4 NBs compared with stage 4s tumors (39). If so, the aggressive behavior of stage 4 NB may be associated with inhibition of UNC5D proapoptotic function by netrin-1 produced by tumor cells.
Previous reports have suggested that the UNC5 family plays a significant role in cancers. Expression of UNC5A–UNC5C is downregulated in various cancers (40). UNC5D is mapped to chromosome 8p12. This region is frequently aberrant in many cancers (41) and may harbor some candidate tumor suppressor genes, such as SFRP1 (42), HTPAP (43), and a breast cancer susceptibility gene (44). UNC5D itself is also included in the homozygously deleted region at D8S87 in prostate cancer (45), in the region with some recurrent breaks in breast cancer (46), and in the deleted region in muscle-invasive bladder cancer (47). In addition, the UNC5D promoter region is hypermethylated in lung cancer (48), which indicates that UNC5D may be a candidate tumor suppressor for various human cancers. However, in NBs, the frequency of allelic loss at the UNC5D locus was only 16%, according to array-CGH analysis of 112 primary NBs (A. Nakagawara, unpublished observations), and promoter hypermethylation was observed at all stages of NB to some extent, without any correlation to prognosis (A. Nakagawara and T. Ushijima, unpublished observations). Nevertheless, UNC5D was upregulated by treatment with both histone deacetylase inhibitors and methylation inhibitors in several NB cell lines (data not shown), which indicates that epigenetic modifications may regulate UNC5D expression in NBs. Importantly, UNC5D was induced in response to NGF deprivation and had the ability to induce cell death in NBs under the condition of netrin-1 deficiency, providing support for the notion that dependent receptor UNC5D may function as a conditional tumor suppressor in NBs.
A putative caspase cleavage site exists in the majority of dependence receptors identified so far (13, 23), which suggests that caspase cleavage is an important event in the regulation of the proapoptotic function of dependence receptors. Cleaved UnICD may translocate into the nucleus (49, 50). In fact, the γ-secretase–generated intracellular domain of DCC translocates into the nucleus and has transcriptional activity (51). In the present study, we uncovered the molecular mechanism of dependence receptor UNC5D-mediated apoptosis through caspase cleavage. Notably, the VDVID416 site in UNC5D was targeted by not only caspase 3, but also caspase 2, distinct from other UNC5 family members. Caspase 2 plays a critical role in intrinsic and extrinsic apoptotic processes as both initiator and effector (52). More importantly, a caspase 2–dependent pathway is required for neuronal cell death induced by NGF deprivation to complete the highly organized nervous system in the body (53). On the other hand, induction and caspase cleavage of UNC5D were observed in several cell lines in response to various apoptotic stimuli besides NGF withdrawal, which indicates that UNC5D is a common proapoptotic molecule involved in various apoptotic signaling pathways.
We showed here that UNC5D exerted its ability to induce apoptosis through translocation of caspase-cleaved UnICD into the nucleus, where it interacts with the E2F1 transcription factor. Of the E2F family members, induction of apoptosis may be mainly executed by E2F1 (32). In response to apoptotic stimuli, E2F1 itself is stabilized, and the target genes involved in activation or execution of apoptotic program are upregulated (31). However, the mechanism underlying gene-specific regulation by which E2F1 selects proproliferative or proapoptotic target genes has never been fully understood. Recently, Lees and colleagues documented that E2F1 forms a transcriptionally active complex with pRB and P/CAF specially recruited to E2F1 apoptotic target genes in response to genotoxic stress (54). Similarly, our findings revealed that nuclear UnICD only selectively enhanced the transcription of proapoptotic targets of E2F1, without significant changes in the targets promoting proliferation and survival, which suggests that nuclear UnICD may be a component of the E2F1 transcriptional complex that modulates the activity of E2F1 for apoptosis induction.
Important roles of p53 and E2F1 as well as caspase 2 during NGF depletion–induced neuronal cell death have long been implicated (6, 8, 9, 53). Considering that UNC5D is a transcriptional target of the p53 family and responds to various apoptotic stimuli, including NGF withdrawal, our present results suggest that UNC5D is involved in NGF deprivation–induced PCD, which contributes to spontaneous regression of NB, and possibly developmentally regulated cell death of neural crest–derived neurons with NGF dependence. Identifying the more detailed signaling pathways may provide tools to develop novel therapeutic strategies against aggressive NBs, which are independent of NGF for cell growth and metastasis.
Patients and tumor samples. 108 fresh NB tumor tissues were obtained from patients who had been diagnosed between 1995 and 1999 in Japan. In all, 29 tumors were stage 1, 16 stage 2, 6 stage 4s, 36 stage 3, and 21 stage 4.
Cell culture, transfection, and RNAi. NB cell lines were cultured in RPMI medium. Other cells used in this study were grown in DMEM medium (Sigma-Aldrich) supplemented with 10% (v/v) FBS. Fugene HD (Roche) was used for cell transfections, following the manufacturer’s instructions. siRNAs were obtained from Dharmacon.
Preparation of the UNC5D-specific antibody. To generate the UNC5D-specific antibody, rabbit antiserum was raised against the peptides (amino acids 937–956) of human UNC5D and purified with the affinity purification column by MBL Co. Ltd. Specificity of the antibody was confirmed by IB analysis.
Generation of Unc5d–/– mice and isolation of primary sympathetic neurons. The Unc5d targeting vector was constructed using a BAC clone isolated from a C57BL/6J mouse genomic library (RPCI-23, 372F8 clone; Invitrogen). The 6.5-kb EcoR V–Sma I fragment spanning upstream of the first exon of Unc5d was used as the long arm, and the 1.2-kb Pst I fragment in the first intron as the short arm. The 1.0-kb Sma I–Pst I fragment containing the first exon served as the targeted sequence. The targeted sequence was replaced by the loxP-PGK-Neo-loxP selection cassette including PGK-DTA. The targeting construct was linearized and electroporated into F1 mouse–derived (129/SvJ × C57BL/6J) ES cells. G418-resistant ES clones were screened by PCR and further verified with Southern blotting using both internal and external probes. Finally, 3 independent germline-transmitting chimeric mice were obtained and used after removing PGK-Neo by cre cRNA microinjection into the zygote.
Sympathetic neurons were obtained by enzymatic dissociation of SCG from P0 newborn mice. 3 × 103 cells/well were plated in 6-well dishes (Collagen Type IV cellware; BD Biosciences) in MEM supplemented with 10% (v/v) FBS, 2 mM uridine (Sigma-Aldrich), 2 mM fluorodeoxyuridine (Sigma-Aldrich), and 50 ng/ml mouse NGF (Harlan) for 5 days. Continuously, cells were cultured with or without 50 ng/ml NGF for the following 3 days and observed every 12 hours. In the NGF depletion group, 1% volume anti-NGF antiserum (Accurate Chemical & Scientific Corp.) was added to the medium.
Semiquantitative and quantitative RT-PCR analysis. Total RNA was prepared using an RNeasy mini kit (Qiagen) according to the manufacturer’s protocol. See Supplemental Methods for details.
Immunofluorescence and immunohistochemistry. Frozen sections of NB clinical samples as well as cultured cells were fixed with 4% (w/v) formaldehyde and then incubated with the corresponding antibodies. Nuclei were stained with DAPI (Vector Laboratories). Cells were visualized under a Fluoview laser scanning confocal microscope (Olympus). NB tissue samples were obtained from the patients in stage 1 who had been found by mass screening at the age of 6 months and had favorable biological characteristics, including age less than 1 year, single copy of MYCN, and favorable histology. Histology of the tissues was shown by H&E staining.
Immunohistochemical analysis was carried out using paraffin-embedded tissues as described previously (55).
Apoptosis assay. Cell death was analyzed using the Trypan blue staining procedure (14). Apoptosis was monitored using an in situ cell death detection Kit (Roche). Nuclei were stained with DAPI.
For apoptosis assay of primary NB cells, cells were fixed in 4% (w/v) paraformaldehyde and stained with DAPI. Percent apoptotic nuclei was counted in 3 separate fields as described previously (56). For PC12 cells, cells were collected at each time point, and FACS analysis was carried out.
Colony formation assay and soft-agar assay. The colony formation assay and soft-agar assay were performed as described previously (57).
IP and IB. IP and IB were performed as described previously (57), using nuclear extracts or whole cell lysates. Whole cell lysates were prepared as described previously (25). See Supplemental Methods for details.
In vitro caspase cleavage assay. See Supplemental Methods and ref. 58.
Luciferase reporter assay. The luciferase reporter assay was conducted using a Dual-Luciferase Reporter Assay System (Promega) as described previously (57). pM-VP16 expression vector was used as a positive control.
Treatment of primary NB cells and PC12 cells with NGF. Primary NB cells were dissected from fresh NB tissues at 4°C, seeded at a density of 1–2 × 105 cells/well in a 6-well plate, and cultured in RPMI/OPI medium (Nissui Pharmaceutical) supplemented with 10% (v/v) FBS and antibiotics. PC12 cells were seeded at a density of 1 × 106 cells per 10-cm dish in DMEM medium supplemented with 5% (v/v) FBS and 10% (v/v) horse serum. NGF was added on the next day at a final concentration of 50 ng/ml. Primary cells were grown for 4 days, and PC12 cells for 6 days, with a change of medium containing NGF every 2–3 days. In the NGF withdrawal group, anti-NGF antibody was added at a final concentration of 0.1 μg/ml. The adherent primary NB cells were subjected to subsequent studies.
For knockdown experiments, PC12 cells were seeded at a density of 2 × 105 cells/well in collagen-coated 6-well plates. Accell siRNA against rat UNC5D (Dharmacon) was transduced into PC12 cells twice for long-term knockdown according to the manufacturer’s protocol. Control Accell siRNA was used as a negative control. Cells were then subjected to NGF treatment.
Statistics. Statistical analysis was performed using Stata 6.0 software (Stata Corp.). 2-tailed Student’s t test was used to explore possible associations between UNC5D expression and other factors. The distinction between high and low levels of UNC5D mRNA was based on the median value of the real-time PCR data (median value, 1.47; P = 0.0032), regardless of tumor stage, MYCN copy number, or survival. Kaplan-Meier survival curves were drawn, and survival distributions were compared using the log-rank test. Cox regression models were used to explore associations among UNC5D, age, MYCN copy number, TRKA, origin, and survival. A P value less than 0.05 was considered significant.
Study approval. Studies using clinical NB samples were approved by the Institutional Review Board of Chiba Cancer Center. Written informed consent was provided by the patients’ parents. The Review Board for Animal Life Science of Chiba Cancer Center approved all animal experiments.
We thank Kohei Akazawa for statistical analysis, Hiroki Nagase for helpful discussion, and Takahiro Inoue for the Unc5d–/– mouse. This work was funded in part by a Grant-in-Aid from the Ministry of Health, Labor, and Welfare of Japan for the Third Term Comprehensive Control Research for Cancer; by a grant from Takeda Science Foundation; by the National Cancer Center Research and Development Fund; and by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (JSPS KAKENHI grants 19591271, 24249061, 21591378, and 24591566).
Address correspondence to: Akira Nakagawara, Division of Biochemistry and Innovative Cancer Therapeutics and Children’s Cancer Research Center, Chiba Cancer Center Research Institute, 666-1 Nitona-Chou, Chuo-Ku, Chiba-city, Chiba 260-8717, Japan. Phone: 81.43.264.5431; Fax: 81.43.265.4459; E-mail: akiranak@chiba-cc.jp.
Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J Clin Invest. 2013;123(7):2935–2947. doi:10.1172/JCI65988.
Seiki Haraguchi’s present address is: Animal Breeding and Reproduction Division, National Agriculture and Food Research Organization, Tsukuba, Japan.